Open AccessPTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
Author(s) -
Federica Catalanotti,
Donavan T. Cheng,
Alexander N. Shoushtari,
Douglas B. Johnson,
Katherine S. Panageas,
Parisa Momtaz,
Catherine Higham,
Helen Won,
James J. Harding,
Taha Merghoub,
Neal Rosen,
Jeffrey A. Sosman,
Michael F. Berger,
Paul B. Chapman,
David B. Solit
Publication year - 2017
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.16.00054
Subject(s) - pten , melanoma , medicine , vemurafenib , loss function , oncology , cancer research , mek inhibitor , cancer , pi3k/akt/mtor pathway , metastatic melanoma , gene , biology , mapk/erk pathway , signal transduction , phenotype , genetics
The clinical use of BRAF inhibitors in patients with melanoma is limited by intrinsic and acquired resistance. We asked whether next-generation sequencing of pretreatment tumors could identify coaltered genes that predict for intrinsic resistance to BRAF inhibitor therapy in patients with melanoma as a prelude to rational combination strategies.